netFormulary
 Report : Medicines with links to NICE 13/06/2021 13:05:28

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Nintedanib 08.01 Formulary NICE TA347 : Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Nintedanib 08.01 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Abatacept 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abciximab 02.09 Restricted Use NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Abemaciclib 08.01.05 Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abemaciclib 08.01.05 Formulary NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abiraterone Acetate 08.03.04.02 Formulary NICE TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone Acetate 08.03.04.02 Formulary NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Aclidinium Bomide 03.01.02 Formulary NICE ESNM8: Chronic obstructive pulmonary disease: aclidinium bromide
Adalimumab 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Restricted Use NICE TA146: Psoriasis - adalimumab
Adalimumab 13.05.03 Restricted Use TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment of arthritis after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Restricted Use NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab
Adalimumab 10.01.03 Restricted Use NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 01.05.03 Formulary NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease
Adefovir Dipivoxil 05.03.03 Restricted Use NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib 08.01.05 Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 08.01 Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA409 : Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alendronic Acid Effervescent tablets 06.06.02 Formulary NICE TA464 - Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Formulary TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Non Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Restricted Use NICE TA264 - Alteplase for treating acute ischaemic stroke
Andexanet alfa 02.08.02 Formulary NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apremilast 10.01.03 Restricted Use NICE TA 433: Apremilast for treating active psoriatic arthritis
Apremilast 13.05.02 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Asfotase alfa 09.08.01 Restricted Use NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia
Atezolizumab 08.02.03 Formulary NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.03 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.02.03 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.02.03 Formulary NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.02.03 Formulary NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Atezolizumab 08.02.03 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.02.03 Formulary NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Atorvastatin 02.12 Formulary NICE CG181 - Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
Avatrombopag 09.01.04 Formulary NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab 08.02.03 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 08.02.03 Formulary NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Axicabtagene ciloleucel 08.02.04 Formulary NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Azacitidine 08.01.03 Formulary TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.03.01 Formulary TA 399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azathioprine 10.01.03 Formulary CG79 The Management of Rheumatoid Arthritis in Adults
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Baricitinib 13.05.03 Formulary NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
Beclometasone and formoterol 03.02 Formulary NICE ESNM53 Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler)
Belimumab 10.01.03 Formulary NICE TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bempedoic acid 02.12 Formulary NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bempedoic acid with ezetimibe 02.12 Formulary NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA214: Bevacizmab in combination with taxane
Bevacizumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
Blinatumomab 08.02.03 Formulary NICE TA589:Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Blinatumomab 08.02.03 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03 Restricted Use NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.05 Restricted Use NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Restricted Use NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Bortezomib 08.01.05 Restricted Use NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Restricted Use NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum neurotoxin Type A 04.12 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brigatinib 08.01.05 Formulary NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
Brodalumab 10.01.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab 11.08.02 Formulary NICE TA672: Brolucizumab for treating wet age-related macular degeneration
Cabazitaxel 08.01.05 Formulary NICE TA391 - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Cangrelor 02.09 Formulary NICE TA351 : Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminatedappraisal)
Cannabidiol 04.08.01 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol 04.08.01 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Caplacizumab 08.02.03 Formulary NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carfilzomib 08.01.05 Formulary NICE TA657: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121:Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab 08.01.05 Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Formulary NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Adalimumab, eternecept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Cetuximab 08.01.05 Restricted Use NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Restricted Use NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Restricted Use NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Restricted Use NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Restricted Use NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Formulary NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Ciclosporin 11.08.01 Formulary TA369 : Ciclosporin for treating dry eye disease that has not improved despitetreatment with artificial tears
Ciclosporin 10.01.03 Formulary CG79 The Management of Rheumatoid Arthritis in Adults
Ciclosporin 01.05.03 Formulary NICE NG130: Ulcerative colitis: management
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Ciprofloxacin 05.01.12 Formulary NICE/PHE Antibiotic Guidance: Summary of antimicrobial prescribing guidance –managing common infections
Cladribine 08.01.03 Formulary NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate inhaler 05.01.07 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Non Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA406 : Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-nonsmall-
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cytarabine-Daunorubicin liposomal 08.01.03 Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabrafenib mesilate 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib mesilate 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib mesilate 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Restricted Use NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Formulary NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary TA597: Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390 : Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Daratumumab 08.01.05 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darolutamide 08.03.04.02 Formulary NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Restricted Use TA265 : Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA349 : Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumerate 13.05.03 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinutuximab 08.02.03 Formulary NICE TA538: Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin hydrochloride 08.01.02 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Formulary NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir-grazoprevir 05.03.03.02 Restricted Use NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies fortreating type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03 Restricted Use NICE TA153: Hepatitis B (chronic) - etecavir
Entrectinib 08.01.05 Formulary NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Entrectinib 08.01.05 Formulary NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Erenumab 04.07.04.02 Formulary NICE TA682: Erenumab for preventing migraine
Eribulin 08.01.05 Formulary NICE TA423- Eribulin for treating advanced or metastatic cancer after 2 or more chemotherapies
Erlotinib 08.01.05 Restricted Use NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Restricted Use NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.05 Formulary TA374 Erlotinib and Gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary TA258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary TA227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 10.01.03 Restricted Use NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Restricted Use NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Etelcalcetide 09.05.01.02 Restricted Use NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Non Formulary NICE TA348 : Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.05 Formulary NICE T432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421:Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous - familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary TA164 Febuxostat for the management of Hyperuricaemia in People with Gout
Filgotinib 10.01.03 Formulary NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
Finasteride 06.04.02 Formulary NICE CG 97 Lower urinary tract symptoms in men;management
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA590 : Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Formoterol/Beclometasone 03.02 Formulary NICE ESNM22 Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment
Fremanezumab 04.07.04.02 Formulary NICE TA631: Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer - not recommended
Galantamine M/R capsules 04.11 Formulary Information from NICE
Galcanezumab 04.07.04.02 Formulary NICE TA659: Galcanezumab for preventing migraine
Gaviscon®Advance 01.01.02 Formulary NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
Gefitinib 08.01.05 Formulary NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE NG85: Pancreatic cancer in adults: diagnosis and management
Gemtuzumab ozogamicin 08.02.03 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 08.01.05 Formulary NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glatiramer acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir - pibrentasvir 05.03.03.02 Restricted Use NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Glycopyrronium Bromide 03.01.02 Formulary NICE ESNM9: Chronic obstructive pulmonary disease: Glycopyrronium Bromide
Golimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA220: Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 01.05.03 Formulary NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Ibandronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid 06.06.02 Formulary NICE TA464 - Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 08.01.05 Formulary NICE TA359 -Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Restricted Use NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Infliximab 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 13.05.03 Non Formulary NICE TA134: Infliximab for psoriasis
Infliximab 01.05.03 Formulary NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA163 - Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 13.05.03 Restricted Use TA134 - Infliximab for the treatment of adults with psoriasis
Inotuzumab ozogamicin 08.02.03 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of chronic hepatitis C
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Irinotecan Hydrochloride 08.01.05 Formulary CG131 - Colorectal cancer: The diagnosis and management of colorectal cancer
Irinotecan Hydrochloride 08.01.05 Formulary TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Isatuximab 08.02.03 Formulary NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 02.06.03 Formulary NICE CG126: Stable angina: management
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 13.05.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 10.01.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lanadelumab 03.04.03 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.02.04 Formulary NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir - Sofosbuvir 05.03.03.02 Restricted Use NICE TA363 - Ledipasvir-sofosbuvir for treating Chronic Hepatitis C
Leflunomide 10.01.03 Formulary CG79 The Management of Rheumatoid Arthritis in Adults
Lenalidomide 08.02.04 Formulary NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Formulary NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide plus Dexamethasone 08.02.04 Formulary NICE TA 586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide plus Dexamethasone 08.02.04 Formulary NICE TA 587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma
Lenvatinib 08.01.05 Formulary NICE TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Letermovir 05.03.02.02 Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Liraglutide 04.05 Formulary NICE TA664: Liraglutide for managing overweight and obesity
Liraglutide 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults:management
Lorlatinib 08.01.05 Formulary NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318 :Lubiprostone for treating chronic idiopathic constipation
Lumacaftor-ivacaftor 08.01.02 Non Formulary TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lusutrombopag 09.01.04 Formulary NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Lutetium (177Lu) oxodotreotide 08.03.04.03 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol Dry Powder 03.07 Formulary TA266 - Mannitol dry powder for inhalation for treating cystic fibrosis
Mannitol inhalation 20 Non Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Mepolizumab 03.04.02 Restricted Use NICE TA671 : Mepolizumab for treating severe refractory eosinophilic asthma
Methotrexate 10.01.03 Formulary CG79 The Management of Rheumatoid Arthritis in Adults
Methylprednisolone 06.03.02 Non Formulary NICE CG8: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid
Mifamurtide 08.02.04 Formulary NICE TA235: Osteosarcoma - mifamurtide
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl Oxalate 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Naldemedine 01.06.06 Formulary NICE TA651: Naldemedine for treating opioid-induced constipation
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid-induced constipation
Naltrexone 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Naltrexone-bupropion 04.05.02 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Neratinib 08.03.04.01 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Niraparib 08.01.05 Formulary NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Niraparib 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Restricted Use TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Restricted Use TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.03 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.03 Formulary NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.02.03 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.03 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.03 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.02.03 Formulary NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.03 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.03 Formulary NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.03 Formulary NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Nivolumab 08.02.03 Formulary NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nusinersen® 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Restricted Use NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 11.08.02 Restricted Use NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
Ofatumumab 08.02.03 Formulary NICE TA344 : Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib 08.01.05 Formulary NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.01.05 Formulary NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Restricted Use NICE TA278 - Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)
Omalizumab 03.04.02 Non Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Ombitasvir with Paritaprevir and Ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Osimertinib 08.01.05 Formulary NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Osimertinib 08.01.05 Formulary NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Osimertinib 08.01.05 Formulary NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Oxaliplatin 08.01.05 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.01.05 Formulary NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Panitumumab 08.01.05 Formulary NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panitumumab 08.01.05 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Parenteral Nutrition 09.03 Non Formulary CG32: Oral nutrition support, enteral tube feeding and Parenteral Nutrition
Patiromer calcium 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
PEGASPARGASE 20 Non Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Beta-1a 08.02.04 Formulary NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.02.03 Formulary NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.02.03 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.02.03 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.02.03 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.02.03 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.02.03 Formulary NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.02.03 Formulary NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.02.03 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.02.03 Formulary NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Pembrolizumab 08.02.03 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.02.03 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.02.03 Formulary NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA190:Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pentosan polysulfate sodium 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Peptac®Liquid 01.01.02 Formulary NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pharmalgen 03.04.02 Restricted Use TA246 - Pharmalgen for the treatment of bee and wasp venom allergy
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 20 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Polatuzumab vedotin 08.02.03 Formulary NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride 01.06.07 Formulary NICE TA211: Prucalopride for the treatment of chronic constipation in women
Raloxifene Hydrochloride 06.04.01.01 Non Formulary NICE TA160: quick reference guide on osteoporosis
Ranibizumab 11.08.02 Formulary NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranolazine 02.06.03 Formulary NICE CG126: Stable angina: management
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.01.05 Formulary NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin 05.01.07 Formulary NICE TA337 : Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA 20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease
Risankizumab 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab iv 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab iv 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab iv 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab iv 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab iv 08.02.03 Formulary NICE TA65: Non-Hodgkin’s lymphoma - rituximab
Rituximab iv 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA335 : Rivaroxaban for preventing adverse outcomes after Acute management of Acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Roflumilast 03.03.03 Restricted Use NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Rucaparib 08.02.04 Formulary NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Formulary NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril with valsartan 02.05.05 Formulary NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 08.02.04 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Sarilumab 10.01.03 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Restricted Use NICE TA350 : Secukinumab for treating moderate to severe plaque psoriasis
Semaglutide 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults:management
Simeprevir 05.03.03.02 Restricted Use NICE TA361 - Simprevir in combination with sofosbuvir for treating genotype 1 or 4 Chronic Hepatitis C
Simeprevir 05.03.03.02 Restricted Use NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Siponimod 08.02.04 Formulary NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir-velpatasvir-voxilaprevir 05.03.03.02 Restricted Use NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Sofosubvir-velpatasvir 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sotagliflozin 06.01.02.03 Formulary NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
Sulfasalazine enteric coated 10.01.03 Formulary CG79 The Management of Rheumatoid Arthritis in Adults
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 08.02.02 Formulary NICE TA482:Immunosuppressive therapy for kidney transplants in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481:Immunosuppressive therapy for kidney transplant in adults
Tacrolimus Ointment 0.03% and 0.10% 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Restricted Use NICE TA252: Hepatitis C (genotype 1) - telaprevir
Telbivudine 05.03.03.01 Restricted Use NICE TA154: Hepatitis B - telbivudine
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temsirolimus 08.01.05 Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Test Drug 01.01 Formulary NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420:Ticagrelor for preventing atherothrombotic ardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel 08.01.05 Formulary NICE TA554: Tisagenlecleucel for treating relapsed orrefractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.01.05 Formulary NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Restricted Use NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tocilizumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Restricted Use NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trametinib 08.01.05 Formulary NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE NG101 Early and locally advanced breast cancer diagnosis and managment
Trastuzumab 08.01.05 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Treosulfan 08.01.01 Formulary NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Trifluridine tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Umeclidinium Bromide 03.01.02 Formulary NICE ESNM52: Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse)
Upadacitinib 10.01.03 Formulary NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
Ustekinumab 01.05.03 Formulary NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 01.05.03 Formulary NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Vemurafenib 08.01.05 Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Vilanterol/Fluticasone furoate 03.02 Formulary NICE ESM34 Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vinorelbine 08.01.04 Formulary NICE CG81 : Advanced breast cancer: Diagnosis and treatment
Vismodegib 08.01.05 Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary TA367 - Vortioxetine for treating major depressive episodes
Zanamivir inhalation 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir inhalation 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
South Staffordshire Joint Formulary